Aru Narendran
Overview
Explore the profile of Aru Narendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
3549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tran S, Sipila P, Thakur S, Zhang C, Narendran A
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672602
PV-10 is a 10% formulation of rose bengal sodium that has potent immunotherapeutic and anti-cancer activity against various tumors, including metastatic melanoma and refractory neuroblastoma. Currently, PV-10 is undergoing clinical...
2.
Sarkar S, Chanda A, Khanolkar R, Lambie M, Ailles L, Bratman S, et al.
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540116
Polo-like-kinase-1 (PLK-1) is a serine/threonine kinase that regulates the cell cycle and acts as an oncogene in multiple cancers, including oral squamous cell carcinoma (OSCC). The loss of PLK-1 can...
3.
Sharma R, Zhang C, Narendran A
Genes (Basel)
. 2023 Oct;
14(10).
PMID: 37895265
The E26-transformation-specific (ETS) transcription factors regulate multiple aspects of the normal hematopoietic system. There is an increasing body of evidence suggesting aberrant ETS activity and its contribution to leukemia initiation...
4.
Gupta M, Kannappan S, Jain M, Douglass D, Shah R, Bose P, et al.
Sci Rep
. 2023 Aug;
13(1):12526.
PMID: 37532697
Survival outcomes for patients with neuroblastoma vary markedly and reliable prognostic markers and risk stratification tools are lacking. We sought to identify and validate a transcriptomic signature capable of predicting...
5.
Sharma R, Incoronato A, Zhang C, Jayanthan A, Shah R, Narendran A
J Pediatr Hematol Oncol
. 2023 Jul;
45(6):e750-e756.
PMID: 37494611
Leukemia, diagnosed in children less than 12 months of age, is a rare condition with an aggressive disease presentation and poor response to conventional chemotherapeutic agents. In addition, the unique...
6.
Tran S, Plant-Fox A, Chi S, Narendran A
Neurooncol Pract
. 2023 Jul;
10(4):322-334.
PMID: 37457224
Atypical teratoid rhabdoid tumors (ATRT) are rare and aggressive embryonal tumors of central nervous system that typically affect children younger than 3 years of age. Given the generally poor outcomes...
7.
Balachandran S, Narendran A
Genes (Basel)
. 2023 Mar;
14(3).
PMID: 36980876
Tumorigenesis, which involves the uncontrolled proliferation and differentiation of cells, has been observed to imitate a variety of pathways vital to embryonic development, motivating cancer researchers to explore the genetic...
8.
McAuley G, Yiu G, Chang P, Newby G, Campo-Fernandez B, Fitz-Gibbon S, et al.
Cell
. 2023 Mar;
186(7):1398-1416.e23.
PMID: 36944331
CD3δ SCID is a devastating inborn error of immunity caused by mutations in CD3D, encoding the invariant CD3δ chain of the CD3/TCR complex necessary for normal thymopoiesis. We demonstrate an...
9.
Standing S, Tran S, Murguia-Favela L, Kovalchuk O, Bose P, Narendran A
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497424
Background: Cancer is the leading cause of disease-related mortality in children and malignancies are more frequently observed in individuals with primary immunodeficiencies (PIDs). This study aimed to identify and highlight...
10.
Grundy M, Narendran A
Front Pediatr
. 2022 Aug;
10:910268.
PMID: 36034555
Clinical trials completed in the last two decades have contributed significantly to the improved overall survival of children with cancer. In spite of these advancements, disease relapse still remains a...